260 related articles for article (PubMed ID: 3754487)
1. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission.
Harker WG; Bauer D; Etiz BB; Newman RA; Sikic BI
Cancer Res; 1986 May; 46(5):2369-73. PubMed ID: 3754487
[TBL] [Abstract][Full Text] [Related]
2. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells.
Wang E; Lee MD; Dunn KW
J Cell Physiol; 2000 Aug; 184(2):263-74. PubMed ID: 10867652
[TBL] [Abstract][Full Text] [Related]
3. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
Harker WG; Sikic BI
Cancer Res; 1985 Sep; 45(9):4091-6. PubMed ID: 4028002
[TBL] [Abstract][Full Text] [Related]
4. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
[TBL] [Abstract][Full Text] [Related]
5. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
6. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
7. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.
Bellamy WT; Dalton WS; Kailey JM; Gleason MC; McCloskey TM; Dorr RT; Alberts DS
Cancer Res; 1988 Nov; 48(22):6365-70. PubMed ID: 3180056
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
9. Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine.
Gosland MP; Gillespie MN; Tsuboi CP; Tofiq S; Olson JW; Crooks PA; Aziz SM
Cancer Chemother Pharmacol; 1996; 37(6):593-600. PubMed ID: 8612315
[TBL] [Abstract][Full Text] [Related]
10. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy.
Angelini A; Di Ilio C; Castellani ML; Conti P; Cuccurullo F
J Biol Regul Homeost Agents; 2010; 24(2):197-205. PubMed ID: 20487633
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effects of a specific mixture of nutrients in the multidrug-resistant human uterine sarcoma MES-SA/Dx5 and the drug-sensitive MES-SA cell lines.
Roomi MW; Kalinovsky T; Roomi NW; Rath M; Niedzwiecki A
Oncol Rep; 2012 Jan; 27(1):17-27. PubMed ID: 21947138
[TBL] [Abstract][Full Text] [Related]
12. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
13. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells.
Gosland MP; Lum BL; Sikic BI
Cancer Res; 1989 Dec; 49(24 Pt 1):6901-5. PubMed ID: 2582432
[TBL] [Abstract][Full Text] [Related]
14. Dipyridamole reverses the resistance to topoisomerase II inhibitors but not to antimicrotubule agents in multidrug-resistant melanoma cells.
Damle B; Desai P
Oncol Res; 1994; 6(2):49-57. PubMed ID: 7949465
[TBL] [Abstract][Full Text] [Related]
15. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
17. Monitoring incorporation, transformation and subcellular distribution of N-l-leucyl-doxorubicin in uterine sarcoma cells using capillary electrophoretic techniques.
Wang Y; Arriaga EA
Cancer Lett; 2008 Apr; 262(1):123-32. PubMed ID: 18194838
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
[TBL] [Abstract][Full Text] [Related]
19. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening.
Wesolowska O; Paprocka M; Kozlak J; Motohashi N; Dus D; Michalak K
Anticancer Res; 2005; 25(1A):383-9. PubMed ID: 15816562
[TBL] [Abstract][Full Text] [Related]
20. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F
Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
